ROLE OF BISPHOSPHONATES IN PROSTHODONTICS – A REVIEW.

International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17328370 Original Article ©2025 RS Publicaon, rspublica[email protected] 115 ROLE OF BISPHOSPHONATES IN PROSTHODONTICS – A REVIEW. Dr. B. LakshmanaRao Prof & HOD, Dept of Prosthodoncs, Lenora Instute of Dental Sciences, Rajahmundry, A.P., Mail: [email protected]om ARTICLE INFO ABSTRACT ©2025 RS Publicaon Paper ID: IJPHC68E92D2F1F6D5 Received: 2025-09-11 Published: 2025-10-11 DOI: https://dx.doi.org /10.5281/zenodo.17 328370 Page No: 115-131 Bisphosphonates (BPs), particularly nitrogen-containing variants (N-BPs) such as zoledronate, alendronate, ibandronate, pamidronate, and risedronate, represent a promising class of bioactive agents for functionalizing implant surface coatings to enhance osseointegration in dental and orthopedic applications. These coatings enable localized drug delivery, directly inhibiting osteoclast-mediated bone resorption via disruption of the mevalonate pathway and farnesyl pyrophosphate synthase, while promoting osteoblast proliferation and differentiation through upregulation of osteogenic genes (e.g., BMP-2, Runx2) and pathways like ERK/JNK. Materials commonly employed include titanium dioxide nanotubes (TNTs), hydroxyapatite (HA), mesoporous silica, and organic polymers (e.g., chitosan, PLGA) for sustained release, achieved via methods such as physical adsorption, covalent grafting, or porous carrier encapsulation. Preclinical studies in sheep and ovariectomized rat models demonstrate superior early mechanical stability (e.g., higher removal torque at 10 days for zoledronate-coated implants) and increased bone-to-implant contact compared to uncoated controls, with no observed necrosis. However, benefits may be time-limited (diminishing by 28 days), and systemic BP use correlates with a 49.96% implant failure rate, mitigated by local coatings that avoid such risks. Challenges include dosedependent cytotoxicity at high concentrations (>10^{-4} M) and limited long-term clinical data. Future directions emphasize hybrid multifunctional coatings integrating N-BPs with growth factors or antimicrobials for personalized, 3D-printed implants, potentially revolutionizing outcomes in osteoporotic patients. Keywords: Bisphosphonates; Nitrogen-containing bisphosphonates; Implant surface coatings; Osseointegration; Dental implants; Zoledronate; Osteoclast inhibition. Introduc!on: Bisphosphonates are a class of anresorpve drugs primarily used to treat condions involving bone loss, such as osteoporosis, Paget's disease, and bone metastases in cancer Interna!onal Journal of Pharmaceu!cal Science and Health Care Available online on h/p://www.rspublicaon.com/ijphc/index.html ISSN 2249 – 5738 Cite This Paper: LakshmanaRao Bathala (2025). "ROLE OF BISPHOSPHONATES IN PROSTHODONTICS – A REVIEW.". INTERNATIONAL JOURNAL PHARMACEUTICAL SCIENCE AND HEALTH CARE (IJPHC), vol. 15, no. 5, 2025, pp. 115-131, DOI: https://dx.doi.org/10.5281/zenodo.17328370 International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17328370 Original Article ©2025 RS Publicaon, rspublica[email protected] 116 paents. They work by binding to hydroxyapate in bone, inhibing osteoclast acvity, and thereby reducing bone resorpon and remodeling. This mechanism can have both beneficial and adverse effects in denstry, where bone healing and remodeling are crical for many procedures. [1] In general denstry, bisphosphonates play a dual role. On the posive side, they have been explored for applicaons in periodontal therapy, where topical or adjuncve use can enhance bone stability, reduce probing pocket depths, and improve outcomes in non-surgical treatments like scaling and root planing. In orthodoncs, they may modulate tooth movement by influencing bone remodeling rates. In endodoncs, there is evidence of their impact on root canal therapy, potenally delaying healing of periapical lesions due to suppressed bone turnover, but also showing potenal in managing certain inflammatory condions. [1,2] However, the primary concern in denstry is the risk of medicaon-related osteonecrosis of the jaw (MRONJ), formerly known as bisphosphonate-related osteonecrosis of the jaw (BRONJ). This condion involves exposed necroc bone in the maxillofacial region that fails to heal for over eight weeks, oCen triggered by invasive dental procedures such as tooth extracons, which can increase the risk significantly (5.3–53 mes higher in some studies). Risk factors include intravenous administraon, prolonged use (especially >4 years), high doses in oncology paents, and local factors like periodontal disease or infecons. Incidence is low in osteoporosis paents (0.001–0.01%) but higher in cancer paents (0.5–4.6%). Prevenve strategies involve pre-treatment dental evaluaons, priorizing conservave treatments (e.g., endodoncs over extracon), anbioc prophylaxis, and good oral hygiene to reduce MRONJ risk by up to 77%. For paents already on bisphosphonates, drug holidays (2–3 months) may be considered before invasive procedures in high-risk cases. [2,3] Role of Bisphosphonates in Prosthodon!cs In prosthodoncs, which focuses on the restoraon and replacement of teeth using prostheses (e.g., dentures, implants, crowns), bisphosphonates pose specific challenges due to their impact on bone healing and integraon. Paents on bisphosphonates, parcularly intravenous forms, have an elevated risk of MRONJ following procedures like dental implant placement or extracons, which can compromise prosthec outcomes. Implants may have higher failure rates due to impaired osseointegraon, and the American College of Prosthodonsts recommends avoiding implants in paents with a history of intravenous bisphosphonates or prolonged oral use (>4 years). Instead, alternaves like removable prostheses are preferred. [4] For paents with acve MRONJ, prosthodonc management emphasizes non-invasive approaches to minimize trauma. This includes using heat-polymerized resilient liners in dentures to distribute pressure evenly and reduce mucosal irritaon, with a minimum liner thickness of 1.5–3 mm. Impressions should use low-pressure techniques, and occlusion International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17328370 Original Article ©2025 RS Publicaon, rspublica[email protected] 117 should employ cuspless teeth to limit stress on compromised bone. Denture wearers on bisphosphonates face a twofold increased MRONJ risk, necessitang frequent relining, smooth borders, and relief over sensive areas like tori or sharp ridges. Follow-up every 2–3 months is crucial, with paents advised to remove prostheses for at least 12 hours daily and report any irritaon promptly. [4,5] In cases of bisphosphonate-induced osteonecrosis, prosthec rehabilitaon can improve quality of life by reducing pain and prevenng secondary infecons, oCen using telescopic overdentures or cover plates as interim soluons unl healing allows definive treatment. Fixed prostheses carry lower risk than removable ones, with supragingival margins to aid hygiene. Overall, a muldisciplinary approach, including pre-treatment evaluaons and riskbenefit assessments, is essenal for safe prosthodonc care in these paents. [6] Uses of Bisphosphonates in Den!stry Bisphosphonates are primarily anresorpve agents that inhibit osteoclast acvity and bone remodeling, used systemically to manage condions involving excessive bone loss. In denstry, their uses are largely indirect, as they are prescribed for systemic condions but impact dental treatment planning and outcomes. They are employed to treat or prevent osteoporosis (including postmenopausal, male, and glucocorcoid-induced forms), Paget's disease of bone, hypercalcemia associated with malignancy, mulple myeloma, and bone metastases from cancers such as breast or prostate cancer. Specific dental applicaons include potenal adjuncve roles in periodontal therapy to reduce bone loss, though evidence is limited. In implant denstry, bisphosphonates have been explored for coang implants (e.g., with zoledronate, pamidronate, or ibandronate) or topical administraon (e.g., clodronate soluon) to enhance osseointegraon, reduce marginal bone loss, and improve implant survival rates, parcularly in paents with compromised bone density. Overall, their use in denstry focuses on managing paents already on therapy to minimize complicaons during procedures like extracons, implants, or periodontal surgery. [1,2,4] Applica!ons of Bisphosphonates in Prosthodon!cs Bisphosphonates are primarily used systemically for bone-related disorders but have specific applicaons in prosthodoncs, focusing on enhancing bone stability and managing complicaons during prosthec treatments. In dental implant procedures, topical applicaons such as bisphosphonate coangs (e.g., zoledronate, pamidronate, or ibandronate) on tanium implants promote osseointegraon by inhibing osteoclast apoptosis and preserving marginal bone, thereby improving implant success rates in paents with compromised bone density, such as those with osteoporosis. Local delivery systems, like alendronate or zoledronate gels, serve as adjuncts to non-surgical periodontal therapy, reducing bone resorpon and probing depths, which indirectly supports prosthec stability by addressing underlying periodontal issues that could affect dentures or fixed prostheses. For removable prostheses and dentures, International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17328370 Original Article ©2025 RS Publicaon, rspublica[email protected] 118 bisphosphonates are applied in managing paents with medicaon-related osteonecrosis of the jaw (MRONJ), where heat-polymerized resilient liners (1.5–3 mm thick) are used to distribute occlusal forces evenly, minimizing mucosal trauma and aiding in rehabilitaon. In cases of established MRONJ, prosthodonc intervenons like telescopic overdentures or cover plates provide interim soluons to improve quality of life by reducing pain and prevenng infecons unl definive treatment is possible. Fixed prostheses may carry lower risks than removable ones, with designs incorporang supragingival margins to facilitate hygiene. Overall, applicaons emphasize prevenve and adapve strategies to accommodate impaired bone remodeling. [4-6] Indica!ons of Bisphosphonates in Prosthodon!cs [1,7,8] Bisphosphonates are indicated in prosthodoncs for paents with underlying condions requiring bone preservaon, where prosthec treatments like implants or dentures are planned. Primary indicaons include osteoporosis (postmenopausal, male, or glucocorcoidinduced), Paget's disease, osteogenesis imperfecta, mulple myeloma, hypercalcemia of malignancy, and bone metastases from cancers (e.g., breast, prostate, lung), administered orally (e.g., alendronate, risedronate, ibandronate) or intravenously (e.g., zoledronate, pamidronate, clodronate). In prosthodonc contexts, they are indicated to support implant osseointegraon in low-risk paents (e.g., oral bisphosphonate use <5 years) by enhancing bone density and reducing resorpon, parcularly when combined with minimally invasive techniques and anbioc prophylaxis. For periodontal management adjuncve to prosthecs, indicaons involve local applicaons to treat periodons, improving bone stability for denture support or implant sites. In MRONJ cases, bisphosphonates' ongoing use necessitates prosthodonc indicaons for non-invasive rehabilitaon, such as resilient-lined dentures, to manage jaw necrosis while maintaining funcon. Muldisciplinary evaluaon is key, priorizing conservave approaches like root canal therapy over extracons to preserve bone for prosthec outcomes. Contraindica!ons of Bisphosphonates in Prosthodon!cs While not absolutely contraindicated, bisphosphonates pose significant risks in prosthodoncs, parcularly due to MRONJ, which involves necroc bone exposure persisng >8 weeks, oCen triggered by invasive procedures. Relave contraindicaons include intravenous administraon (e.g., zoledronate, pamidronate), prolonged use (>2–4 years), and high doses in oncology paents, where MRONJ incidence rises to 1–10%, making dental implants high-risk due to impaired osseointegraon and failure rates averaging 49.96% (higher with IV routes and first-generaon bisphosphonates like clodronate). Comorbidies such as smoking, diabetes, hypertension, poor oral hygiene, periodons, corcosteroid or chemotherapy use, and age >65 act as contraindicaons, increasing implant failure and MRONJ risks (e.g., twofold for denture wearers). For removable dentures, contraindicaons International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17328370 Original Article ©2025 RS Publicaon, rspublica[email protected] 119 involve potenal mucosal trauma leading to MRONJ, necessitang alternaves like fixed prostheses where possible. Elecve invasive procedures (e.g., post-extracve implants, regenerave surgery) are contraindicated in high-risk cases without drug holidays (2–6 months pre/post-surgery) or anbiocs (e.g., amoxicillin/clavulanic acid), though evidence for holidays is limited. In established MRONJ, surgical intervenons are contraindicated unl conservave management (e.g., irrigaon, anbiocs) stabilizes the condion. [1,7,8] Applica!ons of Bisphosphonates in Dental Implants Bisphosphonates (BPs) are anresorpve agents that inhibit osteoclast acvity, primarily used to treat bone disorders such as osteoporosis, Paget's disease, mulple myeloma, hypercalcemia of malignancy, and bone metastases. In the context of dental implants, their applicaons are twofold: systemic administraon in paents requiring implants for underlying bone condions, and local applicaons, such as coangs on implant surfaces, to enhance osseointegraon and bone preservaon. These applicaons aim to improve implant stability and success rates, parcularly in paents with compromised bone quality, while managing associated risks like medicaon-related osteonecrosis of the jaw (MRONJ).[6-8] Systemic Applica!ons Systemically, BPs (administered orally, e.g., alendronate, risedronate, ibandronate, or intravenously, e.g., zoledronate, pamidronate) are applied in paents undergoing dental implant procedures to manage bone loss from condions like osteoporosis or cancer-related bone metastases. This use supports overall bone health, potenally aiding implant integraon by reducing resorpon and improving bone density. Benefits include no absolute contraindicaon for implant therapy in BP users, with studies showing comparable survival rates (e.g., 94.2% at 5 years and 90.1% at 10 years) when protocols like anbioc prophylaxis and minimally invasive techniques are followed. For instance, in paents with osteoporosis, BPs may slightly reduce marginal bone loss over me, enhancing long-term prosthec success. However, risks include a 65.3% higher implant failure rate (odds rao 1.653) compared to nonusers, primarily due to impaired bone remodeling, reduced angiogenesis, and MRONJ (especially with intravenous routes and prolonged use >5 years). Comorbidies like smoking, diabetes, corcosteroids, and periodontal disease further elevate risks. Recommendaons emphasize pre-operave evaluaon, drug holidays for high-risk cases (e.g., intravenous users), and prevenve measures like opmizing oral hygiene and compleng extracons before BP therapy to minimize MRONJ incidence. [7,8] Local Applica!ons [1,9-11] Locally, BPs are applied as coangs on tanium implant surfaces (e.g., with zoledronate, pamidronate, ibandronate, or clodronate) or in gel forms (e.g., alendronate) to promote osseointegraon and preserve peri-implant bone. This applicaon delays osteoclast International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17328370 Original Article ©2025 RS Publicaon, rspublica[email protected] 120 apoptosis, enhances bone-implant contact, and reduces marginal bone loss, making it parcularly useful in paents with low bone density or periodontal defects. Benefits include improved implant stability quoent (ISQ) values, higher removal torque, greater new bone formaon (observed in 82% of studies), and reduced bone loss (e.g., 0.20 mm vs. 0.70 mm over 5 years in coated vs. uncoated implants). No serious side effects like MRONJ have been reported with local use, offering a safer alternave to systemic administraon. Risks are minimal, with some studies showing no difference in outcomes (18% of cases), potenally due to variability in coang methods or paent factors. Recommendaons include using BP coangs for enhanced osseointegraon, especially with adjuncts like scaling and root planing, while calling for more randomized clinical trials to validate long-term efficacy. Overall, while systemic applicaons require careful risk assessment, local BP applicaons show promising potenal for improving dental implant outcomes, though further mulcentric studies with longer follow-ups are needed. [1,9-11] Mechanism of Ac!on of Bisphosphonates in Implant Surface Coa!ngs Bisphosphonates (BPs) are stable analogs of pyrophosphate that primarily funcon as anresorpve agents by inhibing osteoclast acvity, thereby reducing bone resorpon and promong bone formaon around implants. In the context of implant surface coangs, BPs are incorporated to enable localized delivery, which enhances osseointegraon while minimizing systemic side effects such as osteonecrosis. The mechanism involves several key pathways: Inhibi!on of Osteoclast Ac!vity: Nitrogen-containing BPs (N-BPs), such as zoledronate (ZOL), alendronate (ALN), pamidronate (PAM), risedronate (RIS), and ibandronate, target the mevalonate pathway by inhibing farnesyl pyrophosphate synthase, disrupng protein prenylaon, and inducing osteoclast apoptosis. Non-N-BPs, like edronate and clodronate, are metabolized into cytotoxic ATP analogs, also leading to osteoclast apoptosis. This reduces bone resorpon via regulaon of the OPG/RANKL/RANK signaling pathway. Promo!on of Osteoblast and Osteocyte Func!on: BPs smulate osteoblast proliferaon and differenaon by upregulang osteogenic genes (e.g., TGF-β1, VEGF, BMP-2, type-I collagen, osteocalcin) and increasing alkaline phosphatase acvity. They inhibit apoptosis in osteoblasts and osteocytes through acvaon of Src and ERK pathways, enhancing bone formaon and prevenng glucocorcoid-induced cell death. Effects on Bone Mesenchymal Stem Cells (BMSCs): BPs enhance osteogenic differenaon of BMSCs by acvang ERK and JNK pathways, increasing Runx2 expression, and decreasing PPARγ2 acvity, while inhibing adipogenic differenaon. Overall, these acons balance osteogenesis and osteoclast acvity, improving bone-implant contact (BIC), bone volume (BV), and mechanical stability, parcularly in osteoporoc International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17328370 Original Article ©2025 RS Publicaon, rspublica[email protected] 121 condions. Opmal concentraons (e.g., 10^-8 M for proliferaon, <10^-7 M for osteogenic effects) are crucial, as high doses (>10^-4 M) can inhibit cell acvity. Studies show BP-coated implants increase resonance frequency values, removal torque, and new bone formaon in 82% of cases, with no serious side effects like medicaon-related osteonecrosis of the jaw (MRONJ) reported for local use. [11-14] Methods of Coa!ng Implant Surfaces with Bisphosphonates Coang methods for BP-loaded implant surfaces aim to achieve controlled, localized release to enhance osseointegraon. Techniques are categorized into physical, chemical, and carrierbased approaches, oCen using tanium or hydroxyapate (HA) substrates. Key methods include: Physical Adsorp!on: BPs are adsorbed via non-covalent interacons, such as dipping, spray coang, or drop casng. Heparinized surfaces can slow release rates through electrostac adsorpon. Examples include heparin-graCed implants with ALN or ZOL adsorbed on tanium dioxide nanotubes (TNTs) for sustained release. Chemical Bonding: BPs bind to calcium phosphate (CaP) or HA coangs via van der Waals forces, leveraging their affinity for calcium ions. Techniques like plasma spraying or sol-gel methods are used, increasing BIC and BV. Examples include HA coangs with ZOL or ALN. Covalent A@achment: BPs are immobilized using cross-linking agents like EDC/NHS with fibrinogen or amino-silane (APTMS) for stable bonds. Linkers such as silane, polyethylene glycol, heparin, dopamine, or chitosan enhance stability over physical methods. Examples include fibrinogen films with PAM or ibandronate. Carrier Systems and Micro/Nano-Structures: Porous materials like mesoporous TiO2 or SiO2 nanotubes provide high surface area for loading, enabling controlled release. Organic polymers (e.g., chitosan, polycaprolactone, PLGA) encapsulate BPs for biodegradability. Electrochemical methods like anodizaon or electrophorec deposion create TNTs, with diameter and length regulang release (e.g., higher aspect raos slow release). Biomimec coangs incorporate BPs into calcium-deficient HA. Layer-by-layer self-assembly uses electrostac a/racons for polyelectrolyte mullayers. Other techniques include matrix-assisted pulsed laser evaporaon (MAPLE) for ALN-HA films and ion implantaon. These methods ensure sustained release, with studies showing improved outcomes in osteoporoc models.[11-14] Future Trends in Implant Surface Coa!ngs with Bisphosphonates Future trends in implant surface coangs with bisphosphonates (BPs) are increasingly focused on leveraging nanotechnology, advanced drug delivery systems, and bioacve modificaons to enhance osseointegraon, parcularly in challenging condions like osteoporosis, while International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17328370 Original Article ©2025 RS Publicaon, rspublica[email protected] 122 addressing biosafety and infecon risks. Key developments aim to opmize localized BP release to minimize systemic side effects such as medicaon-related osteonecrosis of the jaw (MRONJ), promote bone regeneraon, and integrate mulfunconal properes like anbacterial acvity. [12,14-16] Nanotechnology and Micro/Nano-Structures A prominent trend is the use of nanotechnology to create micro/nano-structures on implant surfaces for controlled BP release and improved osseointegraon. Titanium dioxide nanotubes (TNTs) are emerging as a key plaXorm, where BPs like zoledronate are adsorbed, allowing sustained release regulated by nanotube diameter and length via anodic oxidaon. This approach enhances bone-implant contact in osteoporoc models by inhibing osteoclast acvity and promong osteoblast proliferaon. Nano-scale roughening (under 100 nm) is another future direcon, providing substrates that boost osteoblast behavior and BP absorpon, with commercial applicaons like Osseo-Speed and Nanote paving the way for broader adopon. Graphene-based and nanomaterial coangs are also ancipated to evolve, offering high biocompability and cell smulaon, though experimental challenges like cost and validaon persist. Advanced Drug Delivery and Coa!ng Techniques Future coangs emphasize stable, controlled BP delivery through innovave methods to overcome limitaons in dosage and release kinecs. Covalent graCing using linkers (e.g., silane, polyethylene glycol, heparin, dopamine, chitosan) improves stability over physical adsorpon, enabling precise release. Layer-by-layer self-assembly with polyelectrolytes and encapsulaon in biocompable materials (e.g., chitosan, gelan, polycaprolactone, calcium phosphate) allow for gradual BP eluon, as seen in nanoparcle systems like CS/HA/miRNA21. Biomimec coprecipitaon with hydroxyapate (HA) and plasma spraying are advancing for BP integraon, enhancing mechanical properes and reducing chipping risks. Intermediate layers like fibrinogen between tanium and BPs (e.g., alendronate, pamidronate, ibandronate) are trending for be/er fixaon in human bone. Combina!on Therapies and Mul!func!onal Coa!ngs Integrang BPs with other bioacve agents represents a growing trend to address mulple aspects of implant success. Combinaons with growth factors (e.g., VEGF, BMP), anabolic drugs (e.g., PTH 1–34), inorganic elements (e.g., stronum, magnesium, silicon), and genes (e.g., c-myb via nanoparcles) aim to regulate the osteoporoc microenvironment, promong angiogenesis and osteogenic differenaon. Doped HA coangs with nanoparcles (e.g., SiO2, Ag, Mg) enhance osteogenic and angiogenic properes. Anbacterial enhancements, such as incorporang arficial anmicrobial pepdes (e.g., defensins, cathelicidins), are futurefocused to prevent peri-implans while maintaining BP's an-resorpve benefits. International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17328370 Original Article ©2025 RS Publicaon, rspublica[email protected] 123 Personalized drug-elung systems using nano-carriers and biodegradable materials are emerging for localized delivery, reducing inflammaon and infecon risks. Addressing Osteoporosis and Biosafety In osteoporosis, BP coangs are trending toward local administraon to improve peri-implant bone augmentaon and responses, with synergisc effects from calcium phosphate nanoparcles. Future strategies include regulang macrophage phenotypes (M1 to M2 transion) for inflammaon control and inhibing bacterial biofilms to prevent failures. Biosafety concerns, such as opmizing concentraons to avoid cytotoxicity and ensuring biocompability of degradaon products, are priories for clinical translaon. Emerging Technologies and Research Direc!ons Addive manufacturing (3D prinng) for customized BP-incorporated implants is a key future trend, allowing tailored porosity and bioacve integraon, though long-term effects require more research. Smart implants with nanomaterial biosensors for real-me monitoring of stability and health are nascent but promising. Overall, future direcons emphasize longer clinical trials, dose opmizaon, and comparave studies of local vs. systemic delivery to migate risks like BRONJ and enhance outcomes in compromised bone. [12,14-16] Nitrogen-Containing Bisphosphonate Coated Implants Nitrogen-containing bisphosphonate (N-BP) coated implants are specialized dental or orthopedic implants with surfaces funconalized by coangs incorporang N-BPs, a subclass of bisphosphonates characterized by the presence of nitrogen atoms in their chemical structure, which enhances their potency in inhibing bone resorpon compared to nonnitrogen-containing variants. Common N-BPs used in these coangs include zoledronate (a third-generaon N-BP), alendronate, pamidronate, risedronate, and ibandronate, oCen applied to tanium-based implants to promote localized drug delivery at the bone-implant interface. [17,18] The primary purpose of these coangs is to improve osseointegraon—the direct structural and funconal connecon between the implant and living bone—parcularly in paents with compromised bone quality, such as those with osteoporosis, where systemic bisphosphonate administraon may pose risks like medicaon-related osteonecrosis of the jaw. By providing controlled, site-specific release of N-BPs, the coangs aim to enhance early mechanical stability, increase bone-to-implant contact (BIC), reduce marginal bone loss, and improve long-term implant success rates while minimizing systemic side effects. Mechanism of Ac!on N-BPs in implant coangs primarily act by modulang bone remodeling processes. They inhibit osteoclast acvity through the mevalonate pathway, specifically by targeng farnesyl International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17328370 Original Article ©2025 RS Publicaon, rspublica[email protected] 130 11. Alqhtani NR, Loganathan A, Narayanan S, Alsalleeh F, Weyman K, Jayaraman T. Bisphosphonate releasing dental implant surface coangs and osseointegraon: A systemac review. J Taibah Univ Med Sci. 2017;12(5):369-375. doi:10.1016/j.jtumed.2017.07.003. 12. Li S, Peng F, Cai X, Huang D, Liu Y, Zeng D, Liu H. Dental implants loaded with bioacve agents promote osseointegraon in osteoporosis: A review. Front Bioeng Biotechnol. 2021;9:591796. doi:10.3389/mioe.2021.591796 13. Wang Y, Wang J, Hao H, Zhang M, Tian Q, Ma X, Wang X. Bisphosphonate-incorporated coangs for orthopedic implants funconalizaon. Mater Today Bio. 2023;22:100742. doi:10.1016/j.mtbio.2023.100742 14. Pandey P, Rahman S, Upadhyay A, Nishiyama Y, Neupane GP, Downer M. Customized therapeuc surface coangs for dental implants. Coangs. 2020;10(6):568. doi:10.3390/coangs10060568. 15. James JR, Kharat A, Chinnakun S, Kamble S, Mandal M, Das A. The Future of Dental Implants: A Narrave Review of Trends, Technologies, and Paent Consideraons. Cureus 2025 Aug 18;17(8):e90380. doi: 10.7759/cureus.90380. eCollecon 2025 Aug. 16. Călin M, Păduraru D, Butnaru O, Ianăș A, Măciucă I, Lucaci F, Constannescu C, Dimache A, Stanciu S. Current Trends in Surface Modificaon for Dental Implants—A Review. Eur J Mater Sci Eng. 2024;9(4):246-260. doi:10.36868/ejmse.2024.09.04.246. 17. Mokhtari RA, Kunrath M, Darnaud C, Aludden H, Tollstoy L, Palmquist A, Dahlin C. Osseointegraon of Nitrogen-Containing Bisphosphonate Coangs on Dental Implants: An Experimental Pilot Study. J Biomed Mater Res B Appl Biomater. 2025;113:e35653. doi:10.1002/jbm.b.35653 18. Zhang J, Bai H, Bai M, Wang X, Li Z, Xue H, Wang J, Cui Y, Wang H, Wang Y, Zhou R, Zhu X, Xu M, Zhao X, Liu H. Bisphosphonate-incorporated coangs for orthopedic implants funconalizaon. Mater Today Bio. 2023;22:100737. doi:10.1016/j.mtbio.2023.100737 19. Russell RG. Bisphosphonates: mode of acon and pharmacology. Pediatrics. 2007;119 Suppl 2:S150-62. doi:10.1542/peds.2006-2023H 20. Russell RG, Wa/s NB, Ebeno FH, Rogers MJ. Mechanisms of acon of bisphosphonates: similaries and differences and their potenal influence on clinical efficacy. Osteoporos Int. 2008;19(6):733-59. doi:10.1007/s00198-007-0540-8 21. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999;25(1):97-106. doi:10.1016/s8756-3282(99)00116-7 International Journal of Pharmaceutical Science and Health Care Volume 15, Number 5, 2025 Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 DOI: 10.5281/zenodo.17328370 Original Article ©2025 RS Publicaon, rspublica[email protected] 131 22. Peter B, Piolen DP, Laïb S, et al. Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegraon. Bone. 2005;36(1):52-60. doi:10.1016/j.bone.2004.08.010 23. Rogers MJ. New insights into the molecular mechanisms of acon of bisphosphonates. Curr Pharm Des. 2003;9(32):2643-58. doi:10.2174/1381612033453640 24. Dunford JE, Thompson K, Coxon FP, et al. Structure-acvity relaonships for inhibion of farnesyl diphosphate synthase in vitro and inhibion of bone resorpon in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296(2):235-42. 25. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of acon of bisphosphonates: current status. Clin Cancer Res. 2006;12(20 Pt 2):6222s-6230s. doi:10.1158/1078-0432.CCR-06-0843 26. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell GG, Rogers MJ. Nitrogencontaining bisphosphonates inhibit the mevalonate pathway and prevent posttranslaonal prenylaon of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13(4):581-9. doi:10.1359/jbmr.1998.13.4.581 27. Wang Y, Wang J, Hao H, et al. Bisphosphonate-incorporated coangs for orthopedic implants funconalizaon. Mater Today Bio. 2023;22:100742. doi:10.1016/j.mtbio.2023.100742 28. Chrcanovic BR, Albrektsson T, Wennerberg A. Bisphosphonate treatment and dental implants: A systemac review. Clin Implant Dent Relat Res. 2016;18(4):593-624. doi:10.1111/cid.12337 29. Alqhtani NR, Loganathan A, Narayanan S, Alsalleeh F, Weyman K, Jayaraman T. The Future of Dental Implants: A Narrave Review of Trends, Technologies, and Paent Consideraons. J Clin Med. 2025;14(16):4750. doi:10.3390/jcm14164750.